Prognostic role of phospho-STAT3 in patients with cancers of the digestive system: A systematic review and meta-analysis

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Li, Mu Xing ^a   Bi, Xin Yu ^a   Huang, Zhen ^a   Zhao, Jian Jun ^a   Han, Yue ^a   Li, Zhi Yu ^a   Zhang, Ye Fan ^a   Li, Yuan ^a   Chen, Xiao ^a   Hu, Xu Hui ^a   Zhao, Hong ^a   Cai, Jian Qiang ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; STAT3 PROTEIN; PHOSPHOPROTEIN; STAT3 PROTEIN, HUMAN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DISEASE FREE SURVIVAL; ESOPHAGUS CANCER; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; META ANALYSIS; OVERALL SURVIVAL; PANCREAS CANCER; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOMACH CANCER; SYSTEMATIC REVIEW; TUMOR DIFFERENTIATION; UPREGULATION; BIOSYNTHESIS; DIGESTIVE SYSTEM TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MORTALITY; SURVIVAL RATE;

DIGESTIVE SYSTEM NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PHOSPHOPROTEINS; STAT3 TRANSCRIPTION FACTOR; SURVIVAL RATE;

EID: 84934997390     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127356     Document Type: Article

References (46)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64 (1):9-29. Epub 2014/01/09. doi: 10.3322/caac.21208 PMID: 24399786.
2. Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012; 143(5):1179-1187 e1171-1173. Epub 2012/08/14. doi: 10.1053/j.gastro.2012.08.002 PMID: 22885331; PubMed Central PMCID: PMC3480553.
3. Herszenyi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors. European review for medical and pharmacological sciences. 2010; 14(4):249-258. Epub 2010/05/26. PMID: 20496531.
4. Hari DM, Leung AM, Lee JH, Sim MS, Vuong B, Chiu CG, et al. AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? Journal of the American College of Surgeons. 2013; 217(2):181-190. Epub 2013/06/19. doi: 10.1016/j.jamcollsurg.2013.04.018 PMID: 23768788.
5. Darnell JE Jr. STATs and gene regulation. Science. 1997; 277(5332):1630-1635. Epub 1997/09/12. PMID: 9287210.
6. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity. 2012; 36(4):503-514. Epub 2012/04/24. doi: 10.1016/j.immuni.2012.03.013 PMID: 22520844; PubMed Central PMCID: PMC3909993.
7. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer cell. 2009; 15(2):91-102. Epub 2009/02/03. doi: 10.1016/j.ccr.2009.01.002 PMID: 19185844.
8. Dodd KM, Yang J, Shen MH, Sampson JR, Tee AR. mTORC1 drives HIF-1alpha and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene. 2014;. 10.1038/onc.2014.164. Epub 2014/06/17. doi: 10.1038/onc.2014.164 PMID: 24931163; PubMed Central PMCID: PMC4172452.
9. Tye H, Kennedy CL, Najdovska M, McLeod L, McCormack W, Hughes N, et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer cell. 2012; 22 (4):466-478. Epub 2012/10/20. doi: 10.1016/j.ccr.2012.08.010 PMID: 23079657.
10. Chen SH, Murphy DA, Lassoued W, Thurston G, Feldman MD, Lee WM. Activated STAT3 is a mediator and biomarker of VEGF endothelial activation. Cancer biology & therapy. 2008; 7(12):1994-2003. Epub 2008/11/05. PMID: 18981713; PubMed Central PMCID: PMC2932444.
11. Sonnenblick A, Shriki A, Galun E, Axelrod JH, Daum H, Rottenberg Y, et al. Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2012; 14(3):232-236. Epub 2012/03/01. doi: 10.1007/s12094-012-0789-z PMID: 22374428.
12. Wang M, Chen GY, Song HT, Hong X, Yang ZY, Sui GJ. Significance of CXCR4, phosphorylated STAT3 and VEGF-A expression in resected non-small cell lung cancer. Experimental and therapeutic medicine. 2011; 2(3):517-522. Epub 2011/05/01. doi: 10.3892/etm.2011.235 PMID: 22977534; PubMed Central PMCID: PMC3440730.
13. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clinical cancer research: an official journal of the American Association for Cancer Research. 2002; 8(4):945-954. Epub 2002/04/12. PMID: 11948098.
14. Dobi E, Monnien F, Kim S, Ivanaj A, N'Guyen T, Demarchi M, et al. Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer. Clinical colorectal cancer. 2013; 12(1):28-36. Epub 2012/10/23. doi: 10.1016/j.clcc.2012.09.002 PMID: 23083634.
15. Lee J, Kang WK, Park JO, Park SH, Park YS, Lim HY, et al. Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica. 2009; 117(8):598-606. Epub 2009/08/12. doi: 10.1111/j.1600-0463.2009.02512.x PMID: 19664131.
16. Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ren WH, et al. Activation of STAT3 signal pathway correlates with twist and E-cadherin expression in hepatocellular carcinoma and their clinical significance. The Journal of surgical research. 2012; 174(1):120-129. Epub 2011/02/15. doi: 10.1016/j.jss.2010.10.030 PMID: 21316706.
17. You Z, Xu D, Ji J, Guo W, Zhu W, He J. JAK/STAT signal pathway activation promotes progression and survival of human oesophageal squamous cell carcinoma. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2012; 14(2):143-149. Epub 2012/02/04. doi: 10.1007/s12094-012-0774-6 PMID: 22301404.
18. Denley SM, Jamieson NB, McCall P, Oien KA, Morton JP, Carter CR, et al. Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract. 2013; 17 (5):887-898. Epub 2013/02/26. doi: 10.1007/s11605-013-2168-7 PMID: 23435739.
19. Monnien F, Zaki H, Borg C, Mougin C, Bosset JF, Mercier M, et al. Prognostic value of phosphorylated STAT3 in advanced rectal cancer: a study from 104 French patients included in the EORTC 22921 trial. Journal of clinical pathology. 2010; 63(10):873-878. Epub 2010/09/30. doi: 10.1136/jcp.2010.076414 PMID: 20876317.
20. Inokuchi M, Murayama T, Hayashi M, Takagi Y, Kato K, Enjoji M, et al. Prognostic value of co-expression of STAT3, mTOR and EGFR in gastric cancer. Experimental and therapeutic medicine. 2011; 2 (2):251-256. Epub 2011/03/01. doi: 10.3892/etm.2011.187 PMID: 22977493; PubMed Central PMCID: PMC3440663.
21. Mano Y, Aishima S, Fujita N, Tanaka Y, Kubo Y, Motomura T, et al. Tumor-associated macrophage promotes tumor progression via STAT3 signaling in hepatocellular carcinoma. Pathobiology: journal of immunopathology, molecular and cellular biology. 2013; 80(3):146-154. Epub 2013/02/01. doi: 10.1159/000346196 PMID: 23364389.
22. Chen MF, Chen PT, Lu MS, Lin PY, Chen WC, Lee KD. IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Molecular cancer. 2013; 12:26. Epub 2013/04/09. doi: 10.1186/1476-4598-12-26 PMID: 23561329; PubMed Central PMCID: PMC3667147.
23. Huang C, Huang R, Chang W, Jiang T, Huang K, Cao J, et al. The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma. Neoplasma. 2012; 59(1):52-61. Epub 2011/11/16. doi: 10.4149/neo-2012-007 PMID: 22082308.
24. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in medicine. 1998; 17(24):2815-2834. Epub 1999/01/28. PMID: 9921604.
25. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology. 2010; 25(9):603-605. Epub 2010/07/24. doi: 10.1007/s10654-010-9491-z PMID: 20652370.
26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-634. Epub 1997/10/06. PMID: 9310563; PubMed Central PMCID: PMC2127453.
27. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K, et al. Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncology reports. 2006; 15(6):1445-1451. Epub 2006/05/11. PMID: 16685378.
28. Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, et al. STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(6):1452-1462. Epub 2011/02/12. doi: 10.1158/1078-0432.CCR-10-2694 PMID: 21310826; PubMed Central PMCID: PMC3077111.
29. Yakata Y, Nakayama T, Yoshizaki A, Kusaba T, Inoue K, Sekine I. Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis. International journal of oncology. 2007; 30(2):437-442. Epub 2007/01/05. PMID: 17203226.
30. Deng JY, Sun D, Liu XY, Pan Y, Liang H. STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer. World journal of gastroenterology: WJG. 2010; 16(42):5380-5387. Epub 2010/11/13. PMID: 21072904; PubMed Central PMCID: PMC2980690.
31. Woo S, Lee BL, Yoon J, Cho SJ, Baik TK, Chang MS, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with better prognosis, cell proliferation and hypoxia-inducible factor-1alpha in human gastric cancer. Pathobiology: journal of immunopathology, molecular and cellular biology. 2011; 78(6):295-301. Epub 2011/11/23. doi: 10.1159/000321696 PMID: 22104200.
32. Xiong H, Du W, Wang JL, Wang YC, Tang JT, Hong J, et al. Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer. J Mol Med (Berl). 2012; 90(9):1037-1046. Epub 2012/02/14. doi: 10.1007/s00109-012-0869-0 PMID: 22328012.
33. Deng J, Liang H, Zhang R, Sun D, Pan Y, Liu Y, et al. STAT3 is associated with lymph node metastasis in gastric cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013; 34(5):2791-2800. Epub 2013/07/05. doi: 10.1007/s13277-013-0837-5 PMID: 23824569.
34. Song YY, Sun LD, Liu ML, Liu ZL, Chen F, Zhang YZ, et al. STAT3, p-STAT3 and HIF-1alpha are associated with vasculogenic mimicry and impact on survival in gastric adenocarcinoma. Oncology letters. 2014; 8(1):431-437. Epub 2014/06/25. doi: 10.3892/ol.2014.2059 PMID: 24959290; PubMed Central PMCID: PMC4063567.
35. Wu LJ, Li HX, Luo XT, Lu RZ, Ma YF, Wang R, et al. STAT3 activation in tumor cell-free lymph nodes predicts a poor prognosis for gastric cancer. International journal of clinical and experimental pathology. 2014; 7(3):1140-1146. Epub 2014/04/04. PMID: 24696730; PubMed Central PMCID: PMC3971319.
36. Wu WY, Li J, Wu ZS, Zhang CL, Meng XL, Lobie PE. Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in hepatocellular carcinoma. Experimental and therapeutic medicine. 2011; 2(4):647-653. Epub 2011/07/01. doi: 10.3892/etm.2011.254 PMID: 22977555; PubMed Central PMCID: PMC3440751.
37. Schoppmann SF, Jesch B, Friedrich J, Jomrich G, Maroske F, Birner P. Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expression and prognosis in esophageal cancer. Clinical & experimental metastasis. 2012; 29(6):615-624. Epub 2012/04/10. doi: 10.1007/s10585-012-9475-3 PMID: 22484976.
38. Koperek O, Aumayr K, Schindl M, Werba G, Soleiman A, Schoppmann S, et al. Phosphorylation of STAT3 correlates with HER2 status, but not with survival in pancreatic ductal adenocarcinoma. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica. 2014; 122(6):476-481. Epub 2013/10/30. doi: 10.1111/apm.12194 PMID: 24164699.
39. Zhang HF, Lai R. STAT3 in Cancer-Friend or Foe? Cancers. 2014; 6(3):1408-1440. Epub 2014/07/06. doi: 10.3390/cancers6031408 PMID: 24995504; PubMed Central PMCID: PMC4190548.
40. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. The Biochemical journal. 1998; 334 (Pt 2):297-314. Epub 1998/08/26. PMID: 9716487; PubMed Central PMCID: PMC1219691.
41. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, et al. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer research. 2007; 67(19):9066-9076. Epub 2007/10/03. doi: 10.1158/0008-5472.CAN-07-0575 PMID: 17909010; PubMed Central PMCID: PMC2570961.
42. Lavecchia A, Di Giovanni C, Cerchia C. Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature. Expert opinion on therapeutic patents. 2014; 24(4):383-400. Epub 2014/01/18. doi: 10.1517/13543776.2014.877443 PMID: 24432979.
43. Xiong A, Yang Z, Shen Y, Zhou J, Shen Q. Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention. Cancers. 2014; 6(2):926-957. Epub 2014/04/20. doi: 10.3390/cancers6020926 PMID: 24743778; PubMed Central PMCID: PMC4074810.
44. Taylor CR, Levenson RM. Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment II. Histopathology. 2006; 49(4):411-424. Epub 2006/09/19. doi: 10.1111/j.1365-2559.2006.02513.x PMID: 16978205.
45. Idikio HA. Immunohistochemistry in diagnostic surgical pathology: contributions of protein life-cycle, use of evidence-based methods and data normalization on interpretation of immunohistochemical stains. International journal of clinical and experimental pathology. 2009; 3(2):169-176. Epub 2010/02/04. PMID: 20126585; PubMed Central PMCID: PMC2809997.
46. Kothmaier H, Rohrer D, Stacher E, Quehenberger F, Becker KF, Popper HH. Comparison of formalinfree tissue fixatives: a proteomic study testing their application for routine pathology and research. Archives of pathology & laboratory medicine. 2011; 135(6):744-752. Epub 2011/06/03. doi: 10.1043/2009-0676-OA.1 PMID: 21631267.